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UNDERLYING 
PATHOLOGY 
 According to The World Health 
Organization, depression is the fourth 
leading cause of total disease burden 
and the leading cause of disability 
worldwide.  In the United States, results 
from the National Health and Nutrition 
Examination Survey reflect a 16.2% 
lifetime depression prevalence.  
Symptoms of depression can range from 
mild to severe and can be episodic or 
chronic.  Depression has a high rate of 
comorbidity with multiple chronic 
diseases and other mental health 
disorders, predominately anxiety.  
Unfortunately, few Americans 
diagnosed with depression actually 
receive sufficient treatment and 
symptom management.  Previous 
research has shown that individuals are 
more likely to seek treatment for 
depression in a primary care setting 
than a mental health specialty clinic, 
especially individuals of ethnic and 
racial minority populations.  
Approximately 50% of individuals 
suffering from depression are receiving 
no pharmacological or 
psychotherapeutical services (Shim, 
Baltrus, Ye, & Rust, 2011). Current 
research is investigating the role of 
brain-derived neurotrophic factor 
(BDNF) and the hypothalamic-pituitary-
adrenal axis (HPA), and its role in the 
diagnosis, progression, and treatment of 
depression (U.S. National Library of 
Medicine [NLM], 2000, para. 2).  This 
research provides insight into the 
mechanism of action of antidepressant 
medications and expands the available 
knowledge to facilitate more thorough 
patient education regarding the benefits 
of treatment. 
Educate Patients Regarding: 
•The importance of antidepressant   
medication compliance and continual     
treatment 
•The dual benefits of regular 
exercise 
•The benefits of a healthy diet 
within an appropriate caloric range 
•The role stress plays in depression 
and the benefits of adding a form of 
relaxation therapy to their daily routine 
•The basic pathological process 
involved in depression to assist the 
patient with better understanding of the 
disease process and appropriate coping 
mechanisms 
. 
 According to The World Health 
Organization, depression is the fourth 
leading cause of total disease burden and 
the leading cause of disability worldwide.  
In the United States, results from the 
National Health and Nutrition 
Examination Survey reflect a 16.2% 
lifetime depression prevalence.  
Symptoms of depression can range from 
mild to severe and can be episodic or 
chronic.  Depression has a high rate of 
comorbidity with multiple chronic 
diseases and other mental health 
disorders, predominately anxiety.  
Unfortunately, few Americans diagnosed 
with depression actually receive 
sufficient treatment and symptom 
management.  Previous research has 
shown that individuals are more likely to 
seek treatment for depression in a 
primary care setting than a mental health 
specialty clinic, especially individuals of 
ethnic and racial minority populations.  
Approximately 50% of individuals 
suffering from depression are receiving 
no pharmacological or 
psychotherapeutical services (Shim, 
Baltrus, Ye, & Rust, 2011). Current 
research is investigating the role of brain-
derived neurotrophic factor (BDNF) and 
the hypothalamic-pituitary-adrenal axis 
(HPA), and its role in the diagnosis, 
progression, and treatment of depression 
(U.S. National Library of Medicine [NLM], 
2000, para. 2).  This research provides 
insight into the mechanism of action of 
antidepressant medications and expands 
the available knowledge to facilitate more 
thorough patient education regarding the 
benefits of treatment. 
      The neurobiology mechanisms of 
depression are not well known but are 
hypothesized to be a combination of 
genetic and environmental factors.  For 
the past fifty years the Monoamine 
Hypothesis of Depression has been the 
leading explanation.  This hypothesis is 
based on a deficit or imbalance of 
monoamine neurotransmitters; 
norepinephrine, serotonin, and 
dopamine.  The enhancing effects of 
antidepressants on the monoaminergic 
system provides the primary support 
for this hypothesis.  Clinical response to 
antidepressants only occurs after weeks 
to months of treatment and only 
chronic use is effective.  This 
phenomenon suggests that lasting 
changes in gene expression are 
required for antidepressants efficacy 
(Masi & Brovedani, 2011).  Research 
within the last decade has expanded the 
earlier Monoamine Hypothesis to 
integrate the gene transcription 
element which has been found to play a 
critical role in the diagnosis and 
treatment of depression.  The 
Monoamine Hypothesis of Gene 
Expression has pointed to the role of 
neurotrophic factors, particularly brain-
derived neurotrophic factor.  The 
Neurotrophic Hypothesis of Neuronal 
Development further explores the role 
of BDNF in neuronal development, 
plasticity, and survival (Aricioglu & 
Gumru, 2012). 
      BDNF is initially synthesized as a 
precursor (prepro-BDNF) which then 
cleaves to pro-BDNF and the mature 
form of BDNF (mBDNF).  mBDNF then 
binds with two different receptors at 
the target cell, TrkB and p75.  mBDNF’s 
trophic effects are mediated by TrkB 
receptor activation which is involved 
with promoting synaptic plasticity and 
regulating protein synthesis-dependent 
long-term potentiation, while pro-BDNF 
binds with high affinity to p75 
receptors which are linked to the 
induction of apoptosis (Hill, 2012).  
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IMPLICATIONS FOR 
NURSING CARE 
 The pathophysiology of depression 
plays an integral role in explaining the 
efficacy of treatment and additional 
physiological mechanisms that may be 
involved.  The effects of BDNF levels in 
depressed patients may provide 
resources for additional screening tests, 
diagnostic tests, and tests for 
monitoring treatment efficacy. The HPA 
axis functionality may also provide 
additional testing tools to determine 
what role stress, current or past, is 
contributing to the patients disease 
process.  Lastly, the inclusion of 
education regarding symptoms, 
contributing factors, additional 
therapies, and lifestyle modifications 
may lead to better disease management.                                                
CONCLUSION 
BDNF is present in multiple tissues 
and cell types; skeletal muscles, kidneys, 
retinas, motor neurons, the prostate, and 
the central nervous system.  The highest 
concentration of BDNF is found in the 
dentate gyrus of the hippocampus, the 
cerebral cortex, and the basal forebrain.  
The majority of neurons are formed 
prenatally but parts of the adult brain, 
particularly the hippocampus and the 
olfactory bulb, retain the ability to grow 
new neurons from neural stem cells, 
neurogenesis.  BDNF is one of the most 
active neurotrophins involved in 
stimulating and controlling neurogenesis.  
Patients with depression are found to 
have a reduction of hippocampal volume, 
decreased BDNF expression, and thus 
decreased neurogenesis (Masi & 
Brovedani, 2011). 
It is unclear whether reduced 
hippocampal volume is a result of 
depression or a cause but growing 
research supports a direct link between 
decreased BDNF and depression.  One of 
the hypothetical frameworks which links 
decreased BDNF with depression is the 
Hypothalamic-Pituitary-Adrenal Axis 
Abnormalities and Brain-Derived 
Neurotrophic Factor Hypothesis.  This 
hypothesis provides further insight into 
the environmental factors involved in 
depression.  Acute and chronic stress can 
induce hyperactivity of the hypothalamic-
pituitary-adrenal (HPA) axis  with a 
resultant increase in glucocorticoid levels 
which reduces the expression of BDNF 
and interferes with its binding to the 
TrkB receptor, thus decreasing BDNF 
signaling.  The HPA axis is regulated via a 
negative feedback loop, increased 
glucocorticoids in the bloodstream cause 
an inhibitory response in the 
hypothalamus and the pituitary gland 
which decreases the synthesis of  
corticotropin releasing hormone and 
adrenocorticotropic hormone.  The 
hippocampus also plays a role in this 
negative feedback loop by signaling the 
HPA axis to down-regulate cortisol 
production.  The hippocampus has a high 
density of glucocorticoid receptors and 
increased cortisol levels have been shown 
to lead to neurotoxicity in this area.  This 
perpetuates a vicious cycle of continual 
HPA axis hyperactivation and 
hippocampal damage (Kunugi, Hori, 
Adachi, & Numakawa, 2010). 
 
 
 Research has found that BDNF 
expression in the hippocampus is 
increased with chronic and not with acute 
antidepressant treatment (Kunugi et al., 
2010).  BDNF levels are decreased in 
patients with depression and also 
correlate with the severity of the 
depression.  BDNF levels after chronic 
antidepressant treatment increase to the 
same level found in healthy, non-
depressed individuals.  Due to the central 
role of BDNF in depression, health care 
providers may opt to obtain baseline 
BDNF levels prior to and throughout 
treatment to determine efficacy (Kurita, 
Nishino, Kato, Numata, & Sato, 2012).  
Gender specific considerations may also 
warrant further investigation, estrogen 
receptors co-localize with BDNF-
synthesizing neurons and induce BDNF 
expression therefore, females with 
estrogen deficiencies or of post-
menopausal age may present uniquely 
(Kunugi et al., 2010).  Additional 
therapies that have been reported to 
increase BDNF levels are; zinc 
supplementation, omega-3 fatty acids, 
regular exercise, and caloric restrictions 
(Ranjbar et al., 2014).  The HPA-BDNF 
link also provides useful insights into the 
benefits of stress reduction in the 
treatment of depression, thus regular 
exercise may serve a dual purpose in 
increasing BDNF and decreasing stress.  
Psychotherapy and a daily relaxation 
regimen can also be very useful as 
adjunct therapies. 
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